Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma

• Published in: Molecular cancer therapeutics Vol. 17; no. 5; pp. 1012 - 1023
• Main Authors: Sagnella, Sharon M, Trieu, Jennifer, Brahmbhatt, Himanshu, MacDiarmid, Jennifer A, MacMillan, Alex, Whan, Renee M, Fife, Christopher M, McCarroll, Joshua A, Gifford, Andrew J, Ziegler, David S, Kavallaris, Maria
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research Inc 01.05.2018
• Subjects: Adults; Animal models; Animals; Antibiotics, Antineoplastic - administration & dosage; Apoptosis; Apoptosis - drug effects; Cancer; Cell Line, Tumor; Chemotherapy; Clinical trials; Disease control; Doxorubicin; Doxorubicin - administration & dosage; Drug delivery systems; Drug Delivery Systems - methods; Drug resistance; Epidermal growth factor receptors; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - metabolism; Fluorescence; Humans; Male; Medical treatment; Mice; Mice, SCID; Microscopy; Neuroblastoma; Neuroblastoma - drug therapy; Neuroblastoma - metabolism; Neuroblastoma - pathology; Pediatrics; Penetration; Proteins; Spheroids; Toxicity; Tumors; Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation

Advanced stage neuroblastoma is an aggressive disease with limited treatment options for patients with drug-resistant tumors. Targeted delivery of chemotherapy for pediatric cancers offers promise to improve treatment efficacy and reduce toxicity associated with systemic chemotherapy. The EnGeneIC D...